The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 04, 2020

Filed:

Jul. 02, 2018
Applicant:

Modernatx, Inc., Cambridge, MA (US);

Inventors:

Barry Ticho, Newton, MA (US);

Nadege Briancon-Eris, Wellesley, MA (US);

Zhinan Xia, Wellesley, MA (US);

Athanasios Dousis, Boston, MA (US);

Seymour de Picciotto, Boston, MA (US);

Vladimir Presnyak, Hooksett, NH (US);

Stephen Hoge, Brookline, MA (US);

Iain Mcfadyen, Arlington, MA (US);

Kerry Benenato, Sudbury, MA (US);

Ellalahewage Sathyajith Kumarasinghe, Harvard, MA (US);

Assignee:

ModernaTX, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 15/62 (2006.01); A61K 47/14 (2017.01); C07K 14/64 (2006.01); A61K 31/7105 (2006.01); A61K 47/69 (2017.01); A61P 9/00 (2006.01); A61K 38/17 (2006.01); C07K 16/26 (2006.01); C12N 15/52 (2006.01); A61K 9/127 (2006.01); A61K 38/00 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/64 (2013.01); A61K 31/7105 (2013.01); A61K 38/1796 (2013.01); A61K 47/6929 (2017.08); A61P 9/00 (2018.01); C07K 16/26 (2013.01); C12N 15/52 (2013.01); C12N 15/62 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/31 (2013.01);
Abstract

The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.


Find Patent Forward Citations

Loading…